inclusion criteria: * male or female aged 18 or over * sars-cov-2 infection proven by rt-pcr on a nasopharyngeal sample within 72 hours prior to inclusion in the study * onset of symptoms of viral infection ≤ 7 days * hospitalization required due to hypoxemia (air saturation \< 94% at rest) * presence of radiological pneumopathy (chest x-ray or non-enhanced thoracic ct) * patient affiliated to a social security scheme. * patient capable of giving free, informed and written consent. * patient with a history of sars-cov-2 infection may participate in the study, but this infection must not have occurred within the 3 months prior to his current hospitalization. * patient who has been vaccinated against sars-cov-2 can participate in the study (regardless of the number of doses) * patient not eligible for specific anti-covid treatment authorized in france (ma or early access) and not part of the standard of care at the time of the study * female patient of childbearing age using effective contraception during study participation, the same applies to partners of childbearing age of male patients. male patients must use condoms.

inclusion criteria: * male or female aged 18 or over * sars-cov-2 infection proven by rt-pcr on a nasopharyngeal sample within 72 hours prior to inclusion in the study * onset of symptoms of viral infection ≤ 7 days * hospitalization required due to hypoxemia (air saturation \< 94% at rest) * presence of radiological pneumopathy (chest x-ray or non-enhanced thoracic ct) * patient affiliated to a social security scheme. * patient capable of giving free, informed and written consent. * patient with a history of sars-cov-2 infection may participate in the study, but this infection must not have occurred within the 3 months prior to his current hospitalization. * patient who has been vaccinated against sars-cov-2 can participate in the study (regardless of the number of doses) * patient not eligible for specific anti-covid treatment authorized in france (ma or early access) and not part of the standard of care at the time of the study * female patient of childbearing age using effective contraception during study participation, the same applies to partners of childbearing age of male patients. male patients must use condoms.

inclusion criteria: male or female aged 18 or over sars-cov-2 infection proven by rt-pcr on a nasopharyngeal sample within 72 hours prior to inclusion in the study onset of symptoms of viral infection ≤ 7 days hospitalization required due to hypoxemia (air saturation < 94% at rest) presence of radiological pneumopathy (chest x-ray or non-enhanced thoracic ct) patient affiliated to a social security scheme. patient capable of giving free, informed and written consent. patient with a history of sars-cov-2 infection may participate in the study, but this infection must not have occurred within the 3 months prior to his current hospitalization. patient who has been vaccinated against sars-cov-2 can participate in the study (regardless of the number of doses) patient not eligible for specific anti-covid treatment authorized in france (ma or early access) and not part of the standard of care at the time of the study female patient of childbearing age using effective contraception during study participation, the same applies to partners of childbearing age of male patients. male patients must use condoms.

inclusion criteria: male or female aged 18 or over sars-cov-2 infection proven by rt-pcr on a nasopharyngeal sample within 72 hours prior to inclusion in the study onset of symptoms of viral infection ≤ 7 days hospitalization required due to hypoxemia (air saturation < 94% at rest) presence of radiological pneumopathy (chest x-ray or non-enhanced thoracic ct) patient affiliated to a social security scheme. patient capable of giving free, informed and written consent. patient with a history of sars-cov-2 infection may participate in the study, but this infection must not have occurred within the 3 months prior to his current hospitalization. patient who has been vaccinated against sars-cov-2 can participate in the study (regardless of the number of doses) patient not eligible for specific anti-covid treatment authorized in france (ma or early access) and not part of the standard of care at the time of the study female patient of childbearing age using effective contraception during study participation, the same applies to partners of childbearing age of male patients. male patients must use condoms.